title: Inside the gray zone. New treatments of questionable effectiveness pose cost, safety questions.
authors: Sabriya
authors: S
authors: Rice
mesh_terms: D002986:Clinical Trials as Topic / Q000191:economics / Q000592:standards; D003362:Cost-Benefit Analysis; D003657:Decision Making; D005260:Female; D006801:Humans; D007248:Infertility, Male / Q000191:economics / Q000628:therapy*; D033181:Information Dissemination / Q000379:methods; D008297:Male; D010043:Outcome and Process Assessment, Health Care / Q000191:economics / Q000379:methods / Q000592:standards*; D064872:Patient Care Bundles / Q000191:economics / Q000592:standards*; D061214:Patient Safety / Q000191:economics / Q000592:standards*; D011247:Pregnancy; D011256:Pregnancy Outcome / Q000191:economics / Q000453:epidemiology*; D011358:Product Surveillance, Postmarketing / Q000191:economics / Q000592:standards; D012051:Reimbursement Mechanisms / Q000592:standards / Q000639:trends; D020554:Sperm Injections, Intracytoplasmic / Q000191:economics / Q000592:standards* / Q000706:statistics & numerical data; D013673:Technology Assessment, Biomedical / Q000191:economics / Q000592:standards*; D014481:United States